Ganglioneuromas (GNs) are neural crest cell-derived tumors and rarely occur in the adrenal gland. There are presently no markers that can reliably distinguish benign and malignant neuroendocrine tumors. Here we describe a 63-year-old woman who developed sudden chest pain and hypertension combined with increased stool frequency. An incidental adrenal mass 5 cm in size with a bright signal on T2-weighted magnetic resonance imaging was discovered. Biochemical evaluation and 131 I-metaiodobenzylguanidine (MIBG) scintigraphy were negative. Histopathological examination revealed a mature adrenal GN. Neuroblastoma, the immature form of a GN, is known for deletions on chromosomal locus 1p36, and adrenal tumors frequently show allele loss on 17p. To further elucidate the histo-and pathogenesis of adrenal GN, we performed loss of heterozygosity studies on chromosomal loci 1p34-36 and 17p13 (the p53 gene locus) after careful microdissection of tumor and normal tissue. We did not detect allelic losses at these loci with the informative polymorphic markers used, suggesting that these loci are not involved in tumorigenesis. In addition, immunohistochemical investigation of the GN was positive for vasoactive intestinal peptide, a hormone commonly expressed in ganglion cells. We suggest that in our patient with an adrenal GN, the combination of biochemical, scintigraphic, molecular, immunohistochemical, and histopathological findings are all consistent with the benign morphology of this tumor.
Introduction
Ganglioneuroma (GN) originates from cells of the neural crest that include the sympathetic ganglia and the adrenal medulla. Therefore it is related to pheochromocytoma and neuroblastoma. The majority of GNs are thoracic; adrenal GNs are rare. At present, there are no markers that can reliably distinguish benign and malignant neuroendocrine tumors such as pheochromocytomas and neuroblastomas, although efforts in this direction have been made on the histological, immunohistochemical, biochemical, and molecular levels (Clarke et al. 1998 , Brodeur et al. 2000 , Koch et al. 2002a . Such a distinction is clinically important, because During this episode, she reportedly was not diaphoretic or tachycardic but she did have a severe headache. Her blood pressure (BP) was 240/135 mmHg. She called her primary care physician colleague and was instructed to take 40 mg propranolol instantly. She felt panic and also ingested 0.5 mg alprazolam. She then left the meeting and went home. There, her BP was 210/110 mmHg. She took another 20 mg propranolol and subsequently fell asleep. After an hour, she woke up and went to the emergency department. At that time, her BP was 130/80 mmHg and her chest pain had gone. An electrocardiogram, and cardiac enzyme and troponin levels were normal. Aortic dissection was suspected and she underwent head and chest computed tomography imaging. A left adrenal mass, 5 cm in size, was found. Abdominal magnetic resonance imaging (MRI) confirmed the adrenal mass which showed a bright signal on the T2-weighted image (Fig. 1 ). There was no evidence of metastases. The patient denied a history of prior chest pain episodes, diaphoresis, night sweats, recent infections, flushing, palpitations, weight changes, and recent or old thromboses. However, she reported increased nervousness and loose stools 4-5 times/ day for the last 4 months.
Until this episode, she had not taken any medications and she had no allergies. Her past medical history was negative. Her family history was positive for coronary artery disease (her father died aged 75 years and was found to have a dissecting aortic aneurysm) but was negative for endocrine disorders including multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. She was widowed and had three healthy sons and a healthy sister aged 59 years. She did not smoke and reported drinking half a glass of wine every day.
Given the incidentally discovered adrenal mass and a suspicion for pheochromocytoma, she was referred to the Clinical Center of the National Institutes of Health (NIH) for further evaluation. On physical examination, she had no features of Cushing's syndrome or virilization, had a BP of 130/72 mmHg on 5 mg amlodipine/day, a regular pulse of 60 beats/min, and a weight of 68 kg at a height of 157 cm. The remainder of the physical examination was within normal limits. In particular, she did not have ganglioneuromas of lips, tongue, or conjunctivae; her thyroid gland, lung, heart, abdominal, skin, and neurological examinations were normal.
Laboratory evaluation revealed normal electrolytes including a plasma potassium of 4.4 mmol/l. Her creatinine clearance was 90 ml/min. Liver function tests, lactate dehydrogenase, and complete blood count were normal. In plasma, calcitonin was 8 pg/ml (normal, <14), corticotropin was 10 pg/ml (normal, 9-52) , dehydroepiandrosterone (DHEA) was 190 ng/dl (normal, 50-540), DHEA-sulfate was 0.46 µg/ml (normal, 0.35-4.3), thyrotropin was 0.11 µU/ml (normal, 0.4-4.0), and free thyroxine was 1.3 ng/dl (normal, 0.7-1.8). Twenty-four-hour urinary free cortisol excretion 100 www.endocrinology.org was normal, as were catecholamines except for fractionated normetanephrine (414 µg/day; normal, 52-310) and total metanephrines (537 µg/day; normal, 95-475). Plasma metanephrine was 0.31 nmol/l (normal, < 0.50), normetanephrine was 0.35 nmol/l (normal, < 0.90), epinephrine was 36 pg/ ml (normal if supine, < 110), norepinephrine was 252 pg/ml (normal if supine, < 750), and dopamine was 35 pg/ml (normal, < 30). Recumbent plasma aldosterone was 10 ng/dl, and supine plasma renin activity was 2 ng/ml/h. The patient underwent a persantine-thallium stress test which was negative. A 6 mCi octreoscan was negative as was a 131 Imetaiodobenzylguanidine (MIBG) scan.
The diagnosis of pheochromocytoma or adrenocortical carcinoma was considered and a unilateral left adrenalectomy was performed without complications for the 5 cm mass. Intraoperatively, the blood pressure slightly increased from 128/60 mmgHg to 150/80 mmHg. Histopathological evaluation of the 5×5×4 cm grossly homogenous mass revealed a mature GN (Fig. 2) . Immunohistochemistry with an antibody directed to vasoactive intestinal peptide (VIP) was positive in ganglion cells (Fig. 3) . In serial sections, there was no evidence for a composite tumor with pheochromocytoma or neuroblastoma components. Plasma catecholamine levels including metanephrines on postoperative day 4 were normal. The patient is no longer suffering from frequent loose stools and is doing fine on 6-month follow-up. Her serum potassium level is around 3.7 mmol/l. In retrospect, the patient reported having undergone some emotional stress related to family issues.
Loss of heterozygosity analyses
Tissue was obtained under an Internal Review Board (IRB)-approved protocol at the National Institutes of Health. After evaluating the paraffin-embedded tumor stained with hematoxylin and eosin, representative sections were prepared for microdissection. Under direct light microscopic visualization using a 30-gauge needle, a modified microdissection procedure was performed, as previously described (Zhuang & Vortmeyer 1998) . Samples of non-tumor control tissue were also obtained from the same slides.
We performed loss of heterozygosity (LOH) analyses, using the following polymorphic markers: D1S1646 (mapping to 1p36.3), D1S468 (1p36.3), FGR (1p34-36), TP53 (mapping to 17p13.1, the p53 gene locus), in the presence of [ 32 P]dCTP (0.1 µCi/µl) (Dupont, Merck Pharmaceutical Co., Wilmington, DE, USA). For all the above named primers, PCR conditions using AmpliTaq Gold DNA polymerase (Perkin Elmer Roche, Indianapolis, IN, USA) in a Hybaid Omnigene thermal cycler were as follows: initial denaturation at 95°C for 10 min, then 35 cycles, each with 1 min denaturation at 95°C, 1 min annealing at 57°C, and 1 min extension at 72°C; PCR (A) was completed with a final extension at 72°C for 10 min. The amplicons were resolved on a 6% polyacrylamide gel. Gels were dried and exposed to Kodak XAR film. All PCR reactions were performed in triplicate.
All aforementioned markers were informative ( Fig. 4) : microdissected tumor tissue displayed heterozygosity as did normal non-neoplastic tissue.
Discussion
This case of a sporadic adrenal GN illustrates several important aspects of neural crest-derived adrenal tumors. These tumors are rare and comprise pheochromocytomas, neuroblastomas, ganglioneuroblastomas, and GNs. Paragangliomas are extra-adrenal pheochromocytomas. Adrenal medulla, chemoreceptors (aortic and carotid bodies), vagal body and small groups of cells associated with the cervical, thoracic and abdominal sympathetic ganglia belong to the paraganglion system (reviewed in Whalen et al. 1992 ). There are 'functional', i.e. catecholamine-producing and -secreting pheochromocytomas/paragangliomas, and 'nonfunctional' pheochromocytomas. Histologically, pheochromocytomas/ paragangliomas are composed predominantly of chief cells and sustentacular cells, whereas GNs contain ganglion cells, neurites, and Schwann cells. Most of these tumors are sporadic but a few are familial (Brodeur et al. 2000 , Koch et al. 2002b , Neumann et al. 2002 . The molecular pathogenesis of sporadic adrenal tumors remains largely unknown (Brodeur et al. 2000 , Reincke et al. 2000 , Koch et al. 2002c . By contrast, in hereditary adrenal tumors, one defect is known from birth on the inherited gene mutation or deletion. Subsequent genetic changes may then more easily be put into the context of tumor formation, as recently demonstrated in multiple endocrine neoplasia type 2 (MEN 2)-related tumors and von Hippel-Lindau-associated pheochromocytoma (Bender et al. 2000 , Huang et al. 2000 , 2003 , Koch et al. 2001 . Although there are reports on familial neuroblastomas, linkage analyses did not reveal a defined gene locus (Maris et al. 1996) , leaving the pathogenesis of neuroblastoma widely unknown despite the fact that many genetic alterations including LOH on numerous chromosomal loci 104 www.endocrinology.org are found in this (mostly sporadic) tumor type (reviewed in Brodeur et al. 2000) .
All these neural crest-derived adrenal tumors are developmentally related, arising from a primitive stem cell (Brodeur et al. 2000 , Tischler 2000 . This concept might explain why some neuroblastomas spontaneously regress or become ganglioneuromas, the more differentiated, mature form of a neuroblastoma (Carlsen 1990 , Ambros et al. 1995 . Approximately 90% of neuroblastomas produce and secrete catecholamines, mainly homovanillic acid and dopamine (LaBrosse et al. 1980 , reviewed in Brodeur et al. 2000 , and are positive on MIBG scanning (Geatti et al. 1985 , Brodeur et al. 2000 . In 35% of cases, neuroblastoma is located in the adrenal gland (n=330, National Neuroblastoma Study, Brodew et al. 2000) . Symptoms are mostly related to local compression effects caused by the tumor mass. In contrast, GNs are often discovered incidentally and are usually located in the thorax (Enzinger & Weiss 1995 , Geoerger et al. 2001 . In less than 21% of cases, GNs occur in the adrenal gland (Celik et al. 1996 , Chen et al. 2000 . GNs with high signal intensity on T2-weighted MRI histologically consist of a large amount of myxoid stroma and relatively few cellular and fibrous components (Zhang et al. 2001) . Their size can be up to 18 cm (Chen et al. 2000 , Leavitt et al. 2000 , Geoerger et al. 2001 . The adrenal tumor in our patient was 5 cm. Confusing in this setting may be the so-called composite tumors which make up 4% of intra-adrenal tumors and consist of pheochromocytoma associated with neuroblastoma, ganglioneuroblastoma, or GN (Linnoila et al. 1990 , Tischler 2000 . As in our patient, an adrenal lesion with a bright T2-image on MRI might indicate a GN, pheochromocytoma, composite tumor, or adrenal carcinoma. Most adrenal carcinomas lead to glucocorticoid and/or androgen excess, neither of which were present in our patient, in whom histopathological evaluation of the adrenal lesion clearly indicated a mature GN.
Clinical symptoms of GNs are nonspecific and related to the location site. Despite their generally benign nature, GNs may come to attention by compressing neighboring structures (Hayes et al. 1989 , Geoerger et al. 2001 . Our patient had normal catecholamine levels and presented with nonspecific chest pain, hypertension, and a history of diarrhea. Less than 30% of patients have elevated plasma and urinary catecholamine levels but rarely symptoms of catecholamine excess (Schuman et al. 1984 , Lucas et al. 1994 , Geoerger et al. 2001 . MIBG uptake is less common (57% of cases) than in patients with neuroblastomas (92%) (Geoerger et al. 2001) . In general, MIBG positivity is mainly determined by an active sodium-and chloride-dependent process via the cell membrane norepinephrine transporter, called Uptake 1. False-negative MIBG scans can result from concomitant administration of certain medications including antihypertensive drugs such as labetalol and calcium channel blockers, all of which should be discontinued at least 2 weeks before performing MIBG scanning (Khafagi et al. 1989 , Solanki et al. 1992 . The lower rate of MIBG uptake in GNs might be due to their histological composition. GNs are composed of ganglion cells, neurites, Schwann cells, and fibrous tissue, as shown in our patient (Fig. 2) . Immature elements such as neuroblasts, which can easily take up MIBG (Kimmig et al. 1984 , Leung et al. 1997 , are not part of a mature GN. If neuroblasts are present, the tumor is called ganglioneuroblastoma, an intermediate lesion between the rather mature GN and rather immature/less differentiated neuroblastoma (Shimada et al. 1999a,b) . GNs are Schwannian stromadominant tumors (Katsetos et al. 1994 , Shimada et al. 1999a . Some investigators believe that Schwann cells arrive in neuroblastomas by migrating into the tumor and are able to inhibit proliferation by inducing the differentiation of neuronal/ganglion cells (Ambros et al. 1996) .
In neuroblastoma, LOH is found on many chromosomal loci including deletions in the short arm of chromosome 1 (1p36) which for a long time has been believed to contain a tumor suppressor gene important in malignant transformation (Huang et al. 2001 , reviewed in Brodeur et al. 2000 . Extensive but unsuccessful attempts to identify a 'neuroblastoma gene' on 1p36 may indicate that involvement of 1p36 is associated with tumor progression rather than initiation. This view is also supported by 1p36 LOH being associated with poor prognosis (Ambros et al. 1995 , Caron et al. 1996 . There are apparently two groups of neuroblastomas: one with LOH of 1p36 which is combined with less favorable prognosis and another without LOH of this locus and with good prognosis. In our patient with an adrenal GN, we did not detect LOH at 1p34-36 with the informative polymorphic markers used. This might indicate that the GN was pathogenetically related to and possibly preceded by a neuroblastoma without 1p36 LOH. This further suggests that this locus may not be involved in tumorigenesis of this tumor type, if a tumor suppressor gene is held to be causative. If LOH at 1p36 were associated with tumor progression as stated above, investigation for LOH at this locus becomes important when one considers that there are less mature tumor forms such as ganglioneuroblastomas, the diagnosis of which may often be missed by histopathological evaluation of only selected sections of the specimen.
Inactivation of TP53 is known to occur in more than 50% of all human cancers (Hollstein et al. 1991) . Because genetic alterations of p53 are frequently found in adrenal tumors and have not been studied in ganglioneuroma (Vogan et al. 1993 , Reincke et al. 1994 , Koch et al. 2002c ), we screened our patient's adrenal GN for allelic loss on 17p13.1, the locus for p53. We did not detect LOH, suggesting that this locus also might not be involved in tumor formation or progression. In addition, we interpret our finding of no LOH on 17p13.1 as a more favorable prognostic marker for adrenal GN, because deletions on the p53 locus are commonly identified in more advanced sporadic tumors (Hollstein et al. 1991 , von Deimling et al. 1992 , Koch et al. 2002c ).
In addition to these molecular findings, our patient's GN was positive for VIP which is the product of ganglion cells (Hansen et al. 1980 , Salmi et al. 1988 ). (Increased) VIP expression in GNs and neuroblastomas correlates with a more favorable prognosis (Lacey et al. 1989 , Qualman et al. 1992 . Large amounts of VIP secretion from neuroendocrine tumors may cause severe watery diarrhea (Said & Faloona 1975 , Kaplan et al. 1980 , El Shafie et al. 1983 . In our patient, it remains unclear whether the adrenal GN secreted sufficient amounts of VIP to explain the patient's rather recent history of increased frequency of loose stools, although the cessation/discontinuation of these symptoms after removal of the adrenal GN is suggestive of VIP involvement. On the other hand, patients with VIP-positive tumors such as GNs and neuroblastomas may not have any symptoms or signs of VIP secretion (Kogner 1995) . GNs can also produce and secrete other hormones such as testosterone, indicating the pluripotency of its precursor cell (Mack et al. 1978 , Aguirre & Scully 1983 .
Taken together, in our case of a 63-year-old woman with an incidentally discovered adrenal GN showing a bright signal on T2-weighted MRI, we interpret our combined findings of no LOH on chromosomal loci 1p34-36 and 17p13, negative biochemical and scintigraphic evaluation, positive VIP immunohistochemistry, and histopathological evaluation indicating a mature GN, as favorable prognostic markers.
